Advertisement

Drug Delivery Devices and Propellants

  • Bruce K. Rubin
  • James B. Fink
Part of the Allergy Frontiers book series (ALLERGY, volume 5)

Topical delivery of medications to the airway as medical aerosols is the first line treatment of asthma. Medical aerosols are produced by a range of devices and each device has its own characteristics, method of operation, and target patient population. Aerosol delivery can be a challenge as the structure of the airways is designed to minimize lung penetration of many aerosols found in the air around us; from dust and pollen to airborne pathogens. The smaller the airway, the greater the flow turbulence and therefore, the greater the volume of particles filtered. Thus, delivery of medical aerosols to children is often an order of magnitude less than adults [1]. This challenge is greater in asthma when there is airflow limitation, inflammation, excess mucus secretion, and airway remodeling [2]. Patient education for proper device use is as critical as proper device selection for effective therapy [3, 4]. In this chapter, we discuss the characteristics of aerosol devices and the best techniques for aerosol delivery in patients with asthma.

Keywords

Acute Asthma Inspiratory Flow Beclomethasone Dipropionate Geometric Standard Deviation Dose Inhaler 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rubin BK, Fink JB. Aerosol therapy for children. Resp Care Clinics N Am 2001;7:175–213.CrossRefGoogle Scholar
  2. 2.
    Sangwan S, Agosti JM, Bauer LA, et al. Aerosolized protein delivery in asthma: gamma camera analysis of regional deposition and perfusion. J Aerosol Med 2001;14:185–95.CrossRefPubMedGoogle Scholar
  3. 3.
    Fink JB, Rubin BK. Problems with inhaler use: A call for improved clinician and patient education. Resp Care 2005;50:1360–75.Google Scholar
  4. 4.
    Rubin BK. What does it mean when a patient says, “My asthma medication isn't working”? Chest 2004;126:972–981.CrossRefPubMedGoogle Scholar
  5. 5.
    Reisner C, Katial RK, Bartelson BB. Buchmeir A, Rosenwasser LJ, Nelson HS. Characterization of aerosol output from various nebulizer/compressor combinations. Ann Allergy Asthma Immunol 2001;86:566–74.PubMedCrossRefGoogle Scholar
  6. 6.
    Bennett WD, Brown JS, Zeman KL, Hu SC, Scheuch G, Sommerer K. Targeting delivery of aerosols to different lung regions. J Aerosol Med 2002;15:179–88.CrossRefPubMedGoogle Scholar
  7. 7.
    Darquenne C, Paiva M, Prisk GK. Effect of gravity on aerosol dispersion and deposition in the human lung after periods of breath holding. J Appl Physiol 2000;89:1787–92.PubMedGoogle Scholar
  8. 8.
    Dolovich MB, Killian D, Wolff RK, Obminski G, Newhouse MT. Pulmonary aerosol deposition in chronic bronchitis: intermittent positive pressure breathing vs. quiet breathing. Am Rev Resp Dis 1977;115:397–402.PubMedGoogle Scholar
  9. 9.
    Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, Guyatt G. Device selection and outcomes of aerosol therapy: Evidence-based guidelines. Chest 2005; 127:335–371.CrossRefPubMedGoogle Scholar
  10. 10.
    Meakin BJ, Cainey J, Woodcock PM. Effect of exposure to humidity on terbutaline delivery from turbohaler dry powder inhalation devices. Eur Respir J 1993;6:760–761.PubMedGoogle Scholar
  11. 11.
    Hindle M, Byron PR. Dose emissions from marketed dry powder inhalers. Int J Pharm 1995;116:169–177.CrossRefGoogle Scholar
  12. 12.
    Bisgaard H et al. Inspiratory flow rate through the Diskus/Accuhaler inhaler and Turbuhaler inhaler in children with asthma. J Aerosol Med 1995;8:100.Google Scholar
  13. 13.
    Selam JL. Inhaled insulin for the treatment of diabetes: projects and devices. Expert Opin Pharmacother 2003;4:1373–1377.CrossRefPubMedGoogle Scholar
  14. 14.
    Thiel CG. From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. In: Dalby RN, Byron P, Farr SY, editors. Respiratory drug delivery V. Buffalo Grove: Interpharm Press; 1996:115–123.Google Scholar
  15. 15.
    Montreal Protocol, September 16, 1987, S. Treaty Doc. No. 10, 100th Cong., 1st sess., 26 I. L. M. 1541 (1987) found at http://www.unep.org/ozone/Montreal-Protocol/Montreal-Protocol2000.shtmlGoogle Scholar
  16. 16.
    Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med 2005;18:379–85.CrossRefPubMedGoogle Scholar
  17. 17.
    Lasserson TJ, Cates CK, Jones AB, Steele EH, White J. Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children. Cochrane Database Syst Rev 2006;19(2):CD005309.Google Scholar
  18. 18.
    Kobayashi Y, Yasuba H, Kudou M, Hamada K, Kita H. Esophageal candidiasis as a side effect of inhaled fluticasone propionate dry powder: recovery by switching over to hydrofluoroal-kane-134a beclomethasone dipropionate (HFA-BDP). Int J Clin Pharmacol Ther 2006;44:193–97.PubMedGoogle Scholar
  19. 19.
    Anhoj J, Thorsson L, Bisgaard H. Lung deposition of inhaled drugs increases with age. Am J Resp Crit Care Med 2000;162:1819–22.Google Scholar
  20. 20.
    Rubin BK, Durotoye L. How do patients determine that their metered-dose inhaler is empty? Chest. 2004;126:1134–37.CrossRefPubMedGoogle Scholar
  21. 21.
    Williams RO 3 rd, Barron MK. Influence of temperature on the emitted dose of an oral metered dose inhaler. Drug Dev Ind Pharm 1998;24:1043–1048.CrossRefPubMedGoogle Scholar
  22. 22.
    Hampson NB, Mueller MP. Reduction in patient timing errors using a breath-activated metered dose inhaler. Chest 1994;106:462–465.CrossRefPubMedGoogle Scholar
  23. 23.
    Coates AL, MacNeish CF, Meisner D, Kelemen S, Thibert R, MacDonald J, Vadas E. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 1997;111:1206–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996; 110:498–505.CrossRefPubMedGoogle Scholar
  25. 25.
    Ho SL, Coates AL. Effect of dead volume on the efficiency and the cost to deliver medications in cystic fibrosis with four disposable nebulizers. Can Respir J 1999;6:253–260.PubMedGoogle Scholar
  26. 26.
    Rodrigo GJ. Inhaled therapy for acute adult asthma. Curr Opin Allergy Clin Immunol 2003;3:169–75.CrossRefPubMedGoogle Scholar
  27. 27.
    Katial RK, Reisner C, Buchmeier A, Bartelson BB, Nelson HS. Comparison of three commercial ultrasonic nebulizers. Ann Allergy Asthma Immunol 2000;84:255–61.PubMedGoogle Scholar
  28. 28.
    Nakanishi AN, Lamb BM, Foster CF, Rubin BK. Ultrasonic nebulization of albuterol is no more effective than jet nebulization for the treatment of acute asthma in children. Chest 1997;111:1505–08.CrossRefPubMedGoogle Scholar
  29. 29.
    Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002;47:1406–16.PubMedGoogle Scholar
  30. 30.
    Hochrainer D, Holz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med 2005;18:273–82.CrossRefPubMedGoogle Scholar
  31. 31.
    Berry J, Heimbecher S, Hart JL, Sequeira J. Influence of the metering chamber volume and actuator design on the aerodynamic particle size of a metered dose inhaler. Drug Dev Ind Pharm 2003;29:865–76.CrossRefPubMedGoogle Scholar
  32. 32.
    Zar HJ, Asmus MJ, Weinberg EG. A 500-ml plastic bottle: An effective spacer for children with asthma. Pediatr Allergy Immunol 2002;13:217–22.CrossRefPubMedGoogle Scholar
  33. 33.
    Dolovich MA, MacIntyre NR, Anderson PJ, et al. Consensus statement: aerosols and delivery devices. American Association for Respiratory Care. Respir Care 2000;45:589–96.PubMedGoogle Scholar
  34. 34.
    Barry PW, O'Callaghan C. The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br J Clin Pharmacol 1995;40:76–8.PubMedGoogle Scholar
  35. 35.
    Wildhaber JH. High percentage lung delivery in children from detergent-treated spacers. Pediatr Pulmonol 2000;29:389–393.CrossRefPubMedGoogle Scholar
  36. 36.
    Rubin BK, Fink JB. Optimizing aerosol delivery by pressurized metered dose inhalers. Resp Care 2005;50:1191–97.Google Scholar
  37. 37.
    Shah SA, Berlinski AB, Rubin BK. Force-dependent static dead space of face masks used with holding chambers. Respir Care 2006;51:140–4.PubMedGoogle Scholar
  38. 38.
    Rubin BK, Fink JB. The delivery of inhaled medication to the young child. Pediatr Clin N Am 2003;50:1–15.CrossRefGoogle Scholar
  39. 39.
    Iles R, Lister P, Edmunds AT. Crying significantly reduces absorption of aerosolised drug in infants. Arch Dis Child 1999;81:163–65.CrossRefPubMedGoogle Scholar
  40. 40.
    Lowenthal D, Kattan M. Facemasks versus mouthpieces for aerosol treatment of asthmatic children. Pediatric Pulmon 1992;14:192–96.CrossRefGoogle Scholar
  41. 41.
    Rubin BK. Bye-bye, blow-by. Resp Care 2007 August (in press).Google Scholar
  42. 42.
    GINA Global Strategy for Asthma Management and Prevention. Updated 2003. NIH Publication NO 02-3659.Google Scholar
  43. 43.
    Nakanishi AK, Klasner AK, Rubin BK. A randomized controlled trial of inhaled flunisolide in the management of acute asthma in children. Chest 2003;124:790–94.CrossRefPubMedGoogle Scholar
  44. 44.
    Cates CJ, Rowe BH. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma (Cochrane Review). In: The Cochrane Library, 2000; Issue 2 (CD000052). Oxford: Update Software).Google Scholar
  45. 45.
    Colacone A et al. Continuous nebulization of albuterol (salbutamol) in acute asthma. Chest 1990;97:693–697.CrossRefPubMedGoogle Scholar
  46. 46.
    Hamill RJ, Houston ED, Georghiu PR, Wright CE, Koza MA, Cadle RM, et al. An outbreak of Burkholderia cepacia respiratory tract colonization and infection associated with nebulized albuterol therapy. Ann Intern Med 1995;122:762–766PubMedGoogle Scholar
  47. 47.
    Standaert TA, Morlin GL, Williams-Warren J, Joy P, Pepe MS, Weber A, Ramsey BW. Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. Chest 1998;114:577–86CrossRefPubMedGoogle Scholar
  48. 48.
    Rubin BK. Adherence to asthma therapy: The “blocked receptor”. Pediatr Pulmonol 2004;37:36–37.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Jessie Ball duPont Professor and Chairman of the Department of Pediatrics, Professor of Biomedical EngineeringVirginia Commonwealth UniversityRichmondUSA
  2. 2.Independent ConsultantSan MateoUSA

Personalised recommendations